Cargando…

Concerns about subgroup analyses and reason for stopping remdesivir trial

Detalles Bibliográficos
Autor principal:	Vijayaraghavan, Bharath Kumar Tirupakuzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920529/ https://www.ncbi.nlm.nih.gov/pubmed/35288412 http://dx.doi.org/10.1503/cmaj.81197

Ejemplares similares

The authors respond to “Concerns about subgroup analyses and reason for stopping remdesivir trial”
por: Murthy, Srinivas
Publicado: (2022)

Concerns about the interpretation of subgroup analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2022)

Critical Care Registries: The Next Big Stride?
por: Vijayaraghavan, Bharath Kumar Tirupakuzhi, et al.
Publicado: (2019)

Concerns about the interpretation of subgroup analysis. Reply.
por: Li, Shilong, et al.
Publicado: (2022)

Sepsis Epidemiology and Outcomes in Asia: Advancing the Needle
por: Tirupakuzhi Vijayaraghavan, Bharath Kumar, et al.
Publicado: (2022)

How likely are COVID-19 interventions to benefit the sickest patients?
por: Perner, Anders, et al.
Publicado: (2020)

Breaking Barriers to Reach Farther: A Call for Urgent Action on Tele-ICU Services
por: Ramakrishnan, Nagarajan, et al.
Publicado: (2020)

Critical Care Epidemiology and Research in the Face of a Pandemic: An Opportunity in a Crisis
por: Vijayaraghavan, Bharath Kumar Tirupakuzhi, et al.
Publicado: (2020)

Fluid Resuscitation in Sepsis: Reexamining the Paradigm
por: Madhusudan, Poorna, et al.
Publicado: (2014)

Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial
por: Tirupakuzhi Vijayaraghavan, Bharath Kumar, et al.
Publicado: (2020)

Three simple rules to ensure reasonably credible subgroup analyses
por: Burke, James F, et al.
Publicado: (2015)

Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes
por: Tanniou, Julien, et al.
Publicado: (2016)

Improving Mobility in Critically Ill Patients in a Tertiary Care ICU: Opportunities and Challenges
por: Mohan, Sneha, et al.
Publicado: (2021)

Liver injury in COVID-19: prevalence and association with patient-centered outcomes- an analysis of the international severe acute respiratory and emerging infection consortium (ISARIC) database
por: Bishnu, Saptarshi, et al.
Publicado: (2022)

Amphetamine and atropine interaction: A reason for concern?
por: de Hobaika, Adriano Bechara, et al.
Publicado: (2014)

Absolute vs. relative effects—implications for subgroup analyses
por: Andersen, Lars W.
Publicado: (2021)

Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis
por: Bortoletto, Riccardo, et al.
Publicado: (2022)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Challenges in operationalising clinical trials in India during the COVID-19 pandemic
por: Bassi, Abhinav, et al.
Publicado: (2022)

Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing
por: Trkulja, Vladimir
Publicado: (2021)

Standard Care Versus Awake Prone Position in Adult Nonintubated Patients With Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Infection—A Multicenter Feasibility Randomized Controlled Trial
por: Jayakumar, Devachandran, et al.
Publicado: (2021)

Efficacy of early use of remdesivir: a systematic review of subgroup analysis
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

Concerns about renal safety of HES 130
por: Wiedermann, Christian J, et al.
Publicado: (2013)

Validation of a simplified risk prediction model using a cloud based critical care registry in a lower-middle income country
por: Tirupakuzhi Vijayaraghavan, Bharath Kumar, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Anaphylaxis Due to Remdesivir
por: Hopkins, Brian J., et al.
Publicado: (2021)

Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
por: Granholm, Anders, et al.
Publicado: (2022)

A systematic survey of randomised trials that stopped early for reasons of futility
por: Walter, S. D., et al.
Publicado: (2020)

COVID-19 vaccine wastage in Canada, a reason for concern?
por: Aubrey, Lauren, et al.
Publicado: (2022)

Statistical Concerns About Acupressure on Pain in Cancer Patients With Bone Metastasis Trial
por: Santillan-Garcia, Azucena, et al.
Publicado: (2019)

Uncertainty about the Efficacy of Remdesivir on COVID-19
por: Yoo, Jin-Hong
Publicado: (2020)

Successful management of remdesivir extravasation
por: Conde-Estévez, David, et al.
Publicado: (2022)

Remdesivir for Outpatient Management: Time to Wait, Not to Act
por: Mohapatra, Prasanta Raghab
Publicado: (2022)

Survivorship and (QALY)ty: In Pursuit of a Mirage?
por: Vijayaragavan, Bharath Kumar Tirupakuzhi, et al.
Publicado: (2019)

Reasons for Starting and Stopping Electronic Cigarette Use
por: Pepper, Jessica K., et al.
Publicado: (2014)

The reason to stop infliximab is clearly related to the existence of new alternatives: a correspondence analysis of biologics, reasons to stop, and time periods
por: Uceda, Julia, et al.
Publicado: (2012)

About Plastic Stoppings
Publicado: (1884)

It's Not About the F-Stop
por: Maisel, Jay
Publicado: (2015)

Response to “Statistical Concerns About Acupressure on Pain in Cancer Patients With Bone Metastasis Trial”
por: Serçe, Sibel, et al.
Publicado: (2019)

Concerns about the ‘corporate capture’ of The Academy article
por: Butler, J Lauren, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mlo0gpj1954kgknc1401l16jo7